Hodgkin Lymphoma

Hodgkin lymphoma is one of two major categories of lymphoma. It is distinguished from other types of lymphoma by the presence of one characteristic type of cell, known as the Reed-Sternberg cell. A defining attribute of the Reed-Sternberg cell is its expression of the CD30 antigen. The American Cancer Society estimates that more than 9,000 people will be diagnosed with Hodgkin lymphoma in the United States during 2014.

Hodgkin Lymphoma Clinical Trials

Brentuximab vedotin phase 3 ECHELON-1 trial for frontline treatment of Hodgkin lymphoma

Randomized, two-arm trial of brentuximab vedotin plus AVD versus ABVD for frontline treatment in patients with newly diagnosed advanced classical Hodgkin lymphoma. Study #C25003
Learn more

Brentuximab vedotin phase 3 AETHERA trial

Randomized, double-blind trial evaluating brentuximab vedotin versus placebo for the treatment of patients at high risk of residual Hodgkin lymphoma following autologous stem cell transplant. Enrollment in this trial is complete. Study #SGN35-005
Learn more

Brentuximab vedotin phase 2 trial for frontline treatment of Hodgkin lymphoma in patients age 60 and above
Evaluating the activity and safety of brentuximab vedotin as a single-agent and in combination with other agents in frontline therapy of HL in adults age 60 and older. Study #SGN35-015
Learn more

Brentuximab vedotin phase 1/2 trial in patients with relapsed or refractory Hodgkin lymphoma

Evaluating the safety and efficacy of brentuximab vedotin in combination with bendamustine in patients with relapsed or refractory Hodgkin lymphoma. Study #SGN35-016
Learn more

You are now leaving Seattle Genetics' site. Seattle Genetics does not necessarily endorse the organization associated with this link and takes no responsibility for the content contained therein. This resource link is for informational purposes only. Do you want to continue to the external site and leave SeattleGenetics.com?

No, return to SeattleGenetics.com

Yes, leave SeattleGenetics.com